Icelandic generic drugs company Actavis Group HF is interested in acquiring Merck KgaA's generic drugs ops, reported Financial Times, citing Actavis's CEO Robert Wessman.
'We are preparing a bid,' Wessman told the newspaper, adding: 'Financing for a due diligence is in place.'
A successful deal would make Actavis the world's third largest generic drug company, the newspaper noted.
Rival company Ranbaxy Laboratories Ltd aims to start due diligence procedures next month on Merck's generic drugs unit, which it is considering bidding for in conjunction with private equity firms.
Source
'We are preparing a bid,' Wessman told the newspaper, adding: 'Financing for a due diligence is in place.'
A successful deal would make Actavis the world's third largest generic drug company, the newspaper noted.
Rival company Ranbaxy Laboratories Ltd aims to start due diligence procedures next month on Merck's generic drugs unit, which it is considering bidding for in conjunction with private equity firms.
Source
No comments:
Post a Comment